🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Indivior slumps after profit warning, drug discontinuation

Published 09/07/2024, 12:10
© Reuters.
INDV
-

Investing.com - Indivior stock slumped Tuesday after the U.K. pharmaceutical company issued a 2024 profit warning, and announced that it was discontinuing the sales of its schizophrenia drug Perseris.

At 07:00 ET (11:00 GMT), Indivior shares fell over 36% to 751.25p, to its lowest price this year. 

Indivior cited unfavorable market conditions impacting its top-selling opioid addiction treatment, with the Sublocade drug facing intense competition from the launch of a rival, as well as the end of pandemic-relief measures that has led to loss of coverage in the United States for some people enrolled in government-backed Medicaid plans.

The drugmaker said it now expects to generate $1.150-$1.215 billion in revenues for 2024, down from earlier guidance of $1.240-$1.330 billion, with adjusted operating profits penciled in at $285-$320 million, compared with previous projections of $330-$380 million.

Indivior also said it was taking "decisive action that we believe is in the best interest of shareholders" by discontinuing sales of Perseris.

However, “longer term, Indivior still expects to exit 2025 at a $1bn net revenue run-rate and achieve peak sales >$1.5b,” Jefferies said.

The investment bank maintained a ‘buy’ rating on Indivior, with a 2,390p price target.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.